Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer

被引:39
作者
Porcu, Eleonora [1 ]
Cillo, Giulia Maria [1 ]
Cipriani, Linda [1 ]
Sacilotto, Federica [1 ]
Notarangelo, Leonardo [1 ]
Damiano, Giuseppe [1 ]
Dirodi, Maria [1 ]
Roncarati, Ilaria [1 ]
机构
[1] Univ Bologna, Infertil & IVF Unit, St Orsola Malpighi Univ Hosp, Via Massarenti 13, I-40138 Bologna, Italy
关键词
BRCA; Fertility preservation; Breast cancer; Oocyte cryopreservation; OOCYTE CRYOPRESERVATION; CARRIERS; INSUFFICIENCY; STIMULATION; ASSOCIATION; INFERTILITY; CHEMOTHERAPY; MENOPAUSE;
D O I
10.1007/s10815-019-01658-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes. Methods Prospective study: 67 breast cancer patients between 18 and 40 years old, undergoing a fertility preservation by means of oocyte storage were considered. Inclusions criteria for the study were age between 18 and 40 years old, BMI between 18 and 28, breast cancer neoplasm stage I and II according to American Joint Committee on Cancer classification (2017) and no metastasis. Exclusion criteria: age over 40 years old, BMI < 18 and > 28, breast cancer neoplasm stage III and IV and do not performed the BRCA test. A total of 21 patients had not performed the test and were excluded. Patients were divided into four groups: Group A was composed by 11 breast cancer patients with BRCA 1 mutations, Group B was composed by 11 breast cancer patients with BRCA 2 mutations, Group C was composed by 24 women with breast cancer without BRCA mutations, and Group D (control) was composed by 181 normal women. Results Group A showed significant lower AMH levels compared to Group C and D (1.2 +/- 1.1 vs 4.5 +/- 4.1 p < 0.05 and 1.2 +/- 1.1 vs 3.8 +/- 2.5 p < 0.05). BRCA1 mutated patients showed a significant lower rate of mature oocytes (MII) compared to Group C (3.1 +/- 2.3 vs 7.2 +/- 4.4 p < 0,05) and Group D (3.1 +/- 2.3 vs 7.3 +/- 3.4; p < 0,05). Breast cancer patients needed a higher dose of gonadotropins compared to controls (Group A 2206 +/- 1392 Group B2047.5 +/- 829.9 Group C 2106 +/- 1336 Group D 1597 +/- 709 p < 0,05). No significant differences were found among the groups considering basal FSH levels, duration of stimulation, number of developed follicles, and number of total retrieved oocytes. Regarding BRCA2 mutation, no effect on fertility was shown in this study. Conclusions The study showed that BRCA1 patients had a higher risk of premature ovarian insufficiency (POI) confirmed by a diminished ovarian reserve and a lower number of mature oocytes suitable for cryopreservation.
引用
收藏
页码:709 / 715
页数:7
相关论文
共 34 条
  • [1] Implications of systemic malignancies on human fertility
    Agarwal, A
    Said, TM
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2004, 9 (06) : 673 - 679
  • [2] Diminished ovarian reserve, premature ovarian failure, poor ovarian responder-a plea for universal definitions
    Cohen, J.
    Chabbert-Buffet, N.
    Darai, E.
    [J]. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2015, 32 (12) : 1709 - 1712
  • [3] Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer
    Collins, Ian M.
    Milne, Roger L.
    McLachlan, Sue Anne
    Friedlander, Michael
    Hickey, Martha
    Weideman, Prue C.
    Birch, Kate E.
    Hopper, John L.
    Phillips, Kelly-Anne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3920 - +
  • [4] BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD
    Derks-Smeets, I. A. P.
    van Tilborg, T. C.
    van Montfoort, A.
    Smits, L.
    Torrance, H. L.
    Meijer-Hoogeveen, M.
    Broekmans, F.
    Dreesen, J. C. F. M.
    Paulussen, A. D. C.
    Tjan-Heijnen, V. C. G.
    Homminga, I.
    van den Berg, M. M. J.
    Ausems, M. G. E. M.
    de Rycke, M.
    de Die-Smulders, C. E. M.
    Verpoest, W.
    van Golde, R.
    [J]. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2017, 34 (11) : 1475 - 1482
  • [5] Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis
    Friedler, Shevach
    Koc, Onder
    Gidoni, Yariv
    Raziel, Arieh
    Ron-El, Raphael
    [J]. FERTILITY AND STERILITY, 2012, 97 (01) : 125 - 133
  • [6] Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk
    Giordano, Sara
    Garrett-Mayer, Elizabeth
    Mittal, Navdha
    Smith, Kristin
    Shulman, Lee
    Passaglia, Carolyn
    Gradishar, William
    Pavone, Mary Ellen
    [J]. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2016, 5 (04) : 337 - 343
  • [7] Risk of menopause during the first year after breast cancer diagnosis
    Goodwin, PJ
    Ennis, M
    Pritchard, KI
    Trudeau, M
    Hood, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2365 - 2370
  • [8] BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation
    Gunnala, Vinay
    Fields, Jessica
    Irani, Mohamad
    D'Angelo, Debra
    Xu, Kangpu
    Schattman, Glenn
    Rosenwaks, Zev
    [J]. FERTILITY AND STERILITY, 2019, 111 (02) : 363 - 371
  • [9] Antimullerian hormone levels are lower in BRCA2 mutation carriers
    Johnson, Lauren
    Sammel, Mary D.
    Domchek, Susan
    Schanne, Allison
    Prewitt, Maureen
    Gracia, Clarisa
    [J]. FERTILITY AND STERILITY, 2017, 107 (05) : 1256 - +
  • [10] Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
    Lambertini, M.
    Goldrat, O.
    Ferreira, A. R.
    Dechene, J.
    Azim, H. A., Jr.
    Desir, J.
    Delbaere, A.
    t'Kint de Roodenbeke, M. -D.
    de Azambuja, E.
    Ignatiadis, M.
    Demeestere, I.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (01) : 237 - 243